Junshi and Coherus plan to hustle the latest PD-1 to the FDA after an upbeat PhIII assessment
Four months after its first upbeat interim analysis, Shanghai’s Junshi Biosciences and California biotech Coherus BioSciences are touting a statistically significant improvement in overall survival for patients treated with toripalimab plus chemotherapy as a treatment for advanced squamous or non-squamous NSCLC.
The drug, an anti-PD-1 mAb already approved in China as Tuoyi, previously beat placebo as a first-line treatment when combined with chemotherapy. Among 465 advanced NSCLC patients who have never received therapy (both squamous and nonsquamous), investigators observed a “significant improvement in progression-free survival.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.